LYNBROOK, N.Y., May 11, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical companydeveloping first in class collagenase-based products, today announced that BioSpecifics' President, Tom Wegman, will present at SEVEN, Noble Financial Capital Markets' Seventh Annual Equity Conference on Tuesday,
A live webcast of the presentation can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at www.biospecifics.com, or you may use the link: http://noble.mediasite.com/mediasite/Viewer/?peid=546a50205ba1497a9a06f4122a1b3f071d.
About BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications, three of which include: Dupuytren's contracture, Peyronie's disease, and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium Pharmaceuticals, Inc. markets XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture. Pfizer, Inc. is responsible for marketing XIAPEX® in Europe and has announced European regulatory approval and the first commercial sale in the United Kingdom. Asahi Kasei Pharma Corporation is responsible for marketing XIAFLEX® in Japan. More information about BioSpecifics Technologies Corp. may be found on its website at www.biospecifics.com.
SOURCE BioSpecifics Technologies Corp.
Subscribe to our Free Newsletters!
Discover the amazing health benefits of this ''under-valued'' vegetable called leek. Know the ...
Dehydration occurs when there is depletion of body fluids without adequate replacement. Test your ...
Cardiopulmonary bypass is a technique which allows performing open heart surgical procedures in a ...View All